EGFR and non-small cell lung carcinoma: Meanwhile, immune checkpoint inhibitors are established first- and/or second-line treatments for NSCLC including squamous tumors [49–52], so that EGFR-TKI will likely move to further therapy lines in patients with squamous EGFR wild-type tumors.